In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)

Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is overexpressed in a broad range of malignancies, while absent in most healthy human tissues, making it an attractive diagnostic cancer biomarker and therapeutic target. Although commonly viewed as an intracellular protein, we have demonstrated that PRAME has a membrane bound form with an external epitope targetable with conventional antibodies. We generated a polyclonal antibody (Membrane associated PRAME Antibody 1, MPA1) against an extracellular peptide sequence of PRAME. Binding of MPA1 to recombinant PRAME was evaluated by Enzyme-Linked Immunosorbent Assay (ELISA). Flow cytometry and confocal immunofluorescence microscopy of MPA1 was performed on multiple tumor cell lines. Reverse Transcription Polymerase Chain Reaction (RT-PCR) for PRAME was conducted to compare protein and transcriptional expression levels. We demonstrated a robust proof-of-concept for PRAME targeting in vivo by radiolabeling MPA1 with zirconium-89 (89Zr-DFO-MPA1) and demonstrating high specific uptake in PRAME expressing tumors. To our knowledge, this is the first time a cancer testis antigen has been targeted using conventional antibody technologies. Thus, PRAME can be exploited for multiple clinical applications, including targeted therapy, diagnostic imaging and treatment guidance in a wide-range of malignancies, with minimal off-target toxicity.

[1]  J. Marshall,et al.  A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors , 2011, Journal of immunotherapy.

[2]  M. Zahurak,et al.  Characterization of chronic myeloid leukemia stem cells , 2011, American journal of hematology.

[3]  S. Larson,et al.  Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution. , 2015, Nuclear medicine and biology.

[4]  Niklas Thurfjell.  p63 – from expression to function : studies of normal oral mucosa and squamous cell carcinoma of the head and neck , 2007 .

[5]  L. O’Driscoll,et al.  Prevalence and prognostic and predictive relevance of PRAME in breast cancer , 2008, Breast Cancer Research and Treatment.

[6]  R. Sanyal,et al.  Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect. , 2010, Leukemia research.

[7]  M. Kizaki,et al.  Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia , 2001, British journal of haematology.

[8]  R. Bernards,et al.  The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling , 2005, Cell.

[9]  V. Thorsson,et al.  Integrated Genomic and Proteomic Analyses of Gene Expression in Mammalian Cells*S , 2004, Molecular & Cellular Proteomics.

[10]  A. Simpson,et al.  PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. , 2006, Leukemia research.

[11]  F. Berthold,et al.  The Tumor-Associated Antigen PRAME Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome , 2004, Clinical Cancer Research.

[12]  E. Ballestar,et al.  Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment. , 2012, Leukemia research.

[13]  S. Loening,et al.  Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. , 2002, European urology.

[14]  D. Abou,et al.  In vivo biodistribution and accumulation of 89Zr in mice. , 2011, Nuclear medicine and biology.

[15]  Millard,et al.  PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells , 1998, British journal of haematology.

[16]  P. Coulie,et al.  Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. , 1997, Immunity.

[17]  R. Lempicki,et al.  Comparison of mRNA and Protein Measures of Cytokines following Vaccination with Human Papillomavirus-16 L1 Virus-like Particles , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[18]  F. Prósper,et al.  Epigenetic regulation of PRAME gene in chronic myeloid leukemia. , 2007, Leukemia research.

[19]  Franco H Falcone,et al.  PRAME Is a Golgi-Targeted Protein That Associates with the Elongin BC Complex and Is Upregulated by Interferon-Gamma and Bacterial PAMPs , 2013, PloS one.

[20]  A. Dalgleish,et al.  Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine , 2011, Cancer Immunology, Immunotherapy.

[21]  J. Pollack,et al.  Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. , 2006, Blood.

[22]  Y. Matsuzawa,et al.  Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. , 1996, Cancer research.

[23]  J. Utikal,et al.  Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study , 2016, ESMO Open.

[24]  M. Maio,et al.  Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine , 2004, Cancer Research.

[25]  T. De Pas,et al.  Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.